ICAAC 2015: Scrip Connects With Cidara, MerLion And Paratek
This article was originally published in Scrip
Executive Summary
Scrip caught up with several biopharma executives on Sept. 18 during the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and International Congress of Chemotherapy and Infection (ICC) in San Diego to discuss the status of their anti-infective drug development programs.
You may also be interested in...
BIO Notebook, Day 3: Lilly Expands R&D Site, Sigilon Raises Cash And CytomX Talks Deal Strategy
Day three at the BIO International Convention included an off-site visit to Lilly's newly expanded R&D site as well as conversations with Sigilon about the $23m Series A venture funding round it announced that morning and with CytomX about its dealmaking strategy.
Paratek Antibiotic Meets Non-Inferiority Bar In First Phase III
Paratek's omadacycline was non-inferior to Zyvox (linezolid) in a Phase III clinical trial testing the antibiotics in serious skin infections, but the company's drug will have a broader market that includes pneumonia and urinary tract infections – possibly with reduced competition – if future studies are positive.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.